Tuberculosis and Respiratory Diseases

  • 제81권2호
  • /
  • Pages.91-98
  • /
  • 2018
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

Continued Innovation in Respiratory Care: The Importance of Inhaler Devices

  • 투고 : 2017.10.31
  • 심사 : 2017.11.06
  • 발행 : 2018.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

When it comes to the use in inhalers in the management of chronic obstructive pulmonary diseases, there are many options, considerations and challenges, which health care professionals need to address. Considerations for prescribing and dispensing, administering and following up, education, and adherence; all of these factors impact on treatment success and all are intrinsically linked to the device selected. This review brings together relevant evidence, real-life data and practice tools to assist health care professionals in making decisions about the use of inhalers in the management of chronic obstructive pulmonary diseases. It covers some of the key technical device issues to be considered, the evidence behind the role of inhalers in disease control, population studies which link behaviors and adherence to inhaler devices as well as practice advice on inhaler technique education and the advantages and disadvantages in selecting different inhaler devices. Finally, a list of key considerations to aid health care providers in successfully managing the use of inhaler devices are summarized.

키워드

참고문헌

  1. Haughney J, Price D, Kaplan A, Chrystyn H, Horne R, May N, et al. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med 2008;102:1681-93. https://doi.org/10.1016/j.rmed.2008.08.003
  2. Reddel HK, Sawyer SM, Everett PW, Flood PV, Peters MJ. Asthma control in Australia: a cross-sectional web-based survey in a nationally representative population. Med J Aust 2015;202:492-7. https://doi.org/10.5694/mja14.01564
  3. Nathan RA, Thompson PJ, Price D, Fabbri LM, Salvi S, Gonzalez-Diaz S, et al. Taking aim at asthma around the world: global results of the asthma insight and management survey in the Asia-Pacific region, Latin America, Europe, Canada, and the United States. J Allergy Clin Immunol Pract 2015;3:734-42.e5. https://doi.org/10.1016/j.jaip.2015.04.013
  4. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014;24:14009. https://doi.org/10.1038/npjpcrm.2014.9
  5. Armour CL, Lemay K, Saini B, Reddel HK, Bosnic-Anticevich SZ, Smith LD, et al. Using the community pharmacy to identify patients at risk of poor asthma control and factors which contribute to this poor control. J Asthma 2011;48:914-22. https://doi.org/10.3109/02770903.2011.615431
  6. Sriram KB, Percival M. Suboptimal inhaler medication adherence and incorrect technique are common among chronic obstructive pulmonary disease patients. Chron Respir Dis 2016;13:13-22. https://doi.org/10.1177/1479972315606313
  7. Braido F, Chrystyn H, Baiardini I, Bosnic-Anticevich S, van der Molen T, Dandurand RJ, et al. “Trying, but failing”: the role of inhaler technique and mode of delivery in respiratory medication adherence. J Allergy Clin Immunol Pract 2016;4:823-32. https://doi.org/10.1016/j.jaip.2016.03.002
  8. Newman S. Improving inhaler technique, adherence to therapy and the precision of dosing: major challenges for pulmonary drug delivery. Expert Opin Drug Deliv 2014;11:365-78. https://doi.org/10.1517/17425247.2014.873402
  9. Basheti IA, Reddel HK, Armour CL, Bosnic-Anticevich SZ. Improved asthma outcomes with a simple inhaler technique intervention by community pharmacists. J Allergy Clin Immunol 2007;119:1537-8. https://doi.org/10.1016/j.jaci.2007.02.037
  10. Giraud V, Allaert FA, Roche N. Inhaler technique and asthma: feasability and acceptability of training by pharmacists. Respir Med 2011;105:1815-22. https://doi.org/10.1016/j.rmed.2011.07.004
  11. Goris S, Tasci S, Elmali F. The effects of training on inhaler technique and quality of life in patients with COPD. J Aerosol Med Pulm Drug Deliv 2013;26:336-44. https://doi.org/10.1089/jamp.2012.1017
  12. Harnett CM, Hunt EB, Bowen BR, O'Connell OJ, Edgeworth DM, Mitchell P, et al. A study to assess inhaler technique and its potential impact on asthma control in patients attending an asthma clinic. J Asthma 2014;51:440-5.
  13. Lavorini F, Fontana GA, Usmani OS. New inhaler devices: the good, the bad and the ugly. Respiration 2014;88:3-15. https://doi.org/10.1159/000363390
  14. Newman SP. Can lung deposition data act as a surrogate for the clinical response to inhaled asthma drugs? Br J Clin Pharmacol 2000;49:529-37.
  15. Newman SP, Wilding IR, Hirst PH. Human lung deposition data: the bridge between in vitro and clinical evaluations for inhaled drug products? Int J Pharm 2000;208:49-60. https://doi.org/10.1016/S0378-5173(00)00538-X
  16. Capstick TG, Clifton IJ. Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma. Expert Rev Respir Med 2012;6:91-101. https://doi.org/10.1586/ers.11.89
  17. Dalby RN, Eicher J, Zierenberg B. Development of Respimat((R)) soft mist inhaler and its clinical utility in respiratory disorders. Med Devices (Auckl) 2011;4:145-55.
  18. Cheng YS. Mechanisms of pharmaceutical aerosol deposition in the respiratory tract. AAPS PharmSciTech 2014;15:630-40. https://doi.org/10.1208/s12249-014-0092-0
  19. Bonini M, Usmani OS. The importance of inhaler devices in the treatment of COPD. COPD Res Pract 2015;1:9. https://doi.org/10.1186/s40749-015-0011-0
  20. Donnell D. Optimizing drug delivery to the lung: design of a CFC-free corticosteroid metered-dose aerosol system. Drug Dev Ind Pharm 2001;27:111-8. https://doi.org/10.1081/DDC-100000477
  21. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:600-12. https://doi.org/10.1046/j.1365-2125.2003.01893.x
  22. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56:588-99. https://doi.org/10.1046/j.1365-2125.2003.01892.x
  23. Usmani OS. Small-airway disease in asthma: pharmacological considerations. Curr Opin Pulm Med 2015;21:55-67. https://doi.org/10.1097/MCP.0000000000000115
  24. Chrystyn H. Is total particle dose more important than particle distribution? Respir Med 1997;91 Suppl A:17-9. https://doi.org/10.1016/S0954-6111(97)90100-1
  25. Chrystyn H. Anatomy and physiology in delivery: can we define our targets? Allergy 1999;54 Suppl 49:82-7.
  26. Chege JK, el-Araud KA, Clark BJ, Chrystyn H. Optimal particle size for aerosols. Thorax 1997;52:586-7.
  27. Chrystyn H. Is inhalation rate important for a dry powder inhaler? Using the In-Check Dial to identify these rates. Respir Med 2003;97:181-7.
  28. Ciciliani AM, Langguth P, Wachtel H. In vitro dose comparison of Respimat((R)) inhaler with dry powder inhalers for COPD maintenance therapy. Int J Chron Obstruct Pulmon Dis 2017;12:1565-77.
  29. Dolovich MB, Ahrens RC, Hess DR, Anderson P, Dhand R, Rau JL, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005;127:335-71. https://doi.org/10.1378/chest.127.1.335
  30. Brocklebank D, Ram F, Wright J, Barry P, Cates C, Davies L, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001;5:1-149.
  31. Sanchis J, Gich I, Pedersen S, Aerosol Drug Management Improvement Team (ADMIT). Systematic review of errors in inhaler use: has patient technique improved over time? Chest 2016;150:394-406. https://doi.org/10.1016/j.chest.2016.03.041
  32. Global Initiative for Chronic Obstructive Lung Disease. GOLD reports. Global Initiative for Chronic Obstructive Lung Disease; 2017.
  33. Deweerdt S. Global strategy for asthma management and prevention. Bethesda: Global Initiative for Asthma; 2016.
  34. Price DB, Roman-Rodriguez M, McQueen RB, Bosnic-Anticevich S, Carter V, Gruffydd-Jones K, et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J Allergy Clin Immunol Pract 2017;5:1071-81.e9. https://doi.org/10.1016/j.jaip.2017.01.004
  35. Molimard M, Raherison C, Lignot S, Balestra A, Lamarque S, Chartier A, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J 2017;49:1601794. https://doi.org/10.1183/13993003.01794-2016
  36. National Asthma Council Australia. Inhaler technique for people with asthma or COPD. South Melbourne: National Asthma Council Australia; 2016.
  37. National Asthma Council Australia. How to-videos 2017 [Internet]. South Melbourne: National Asthma Council Australia; 2017 [cited 2017 Oct 23]. Available from: https://www.nationalasthma.org.au/health-professionals/how-to-videos.
  38. NPSMedicineWise. 2017 Inhaler devices for respiratory medicines 2017 [Internet]. Strawberry Hills: NPSMedicine-Wise; 2017 [cited 2017 Oct 23]. Available from: https://www.nps.org.au/medical-info/consumer-info/inhaler-devices-forrespiratory-medicines.
  39. Basheti IA, Reddel HK, Armour CL, Bosnic-Anticevich SZ. Counseling about turbuhaler technique: needs assessment and effective strategies for community pharmacists. Respir Care 2005;50:617-23.
  40. Bosnic-Anticevich SZ, Sinha H, So S, Reddel HK. Metereddose inhaler technique: the effect of two educational interventions delivered in community pharmacy over time. J Asthma 2010;47:251-6. https://doi.org/10.3109/02770900903580843
  41. Axtell S, Haines S, Fairclough J. Effectiveness of various methods of teaching proper inhaler technique. J Pharm Pract 2017;30:195-201. https://doi.org/10.1177/0897190016628961
  42. Levy ML, Dekhuijzen PN, Barnes PJ, Broeders M, Corrigan CJ, Chawes BL, et al. Inhaler technique: facts and fantasies: a view from the Aerosol Drug Management Improvement Team (ADMIT). NPJ Prim Care Respir Med 2016;26:16017. https://doi.org/10.1038/npjpcrm.2016.17
  43. Bosnic-Anticevich S, Callan C, Chrystyn H, Lavorini F, Nikolaou V, Kritikos V, et al. Inhaler technique mastery and maintenance in healthcare professionals trained on different devices. J Asthma 2018;55:79-88. https://doi.org/10.1080/02770903.2017.1310227
  44. Toumas-Shehata M, Price D, Basheti IA, Bosnic-Anticevich S. Exploring the role of quantitative feedback in inhaler technique education: a cluster-randomised, two-arm, parallelgroup, repeated-measures study. NPJ Prim Care Respir Med 2014;24:14071. https://doi.org/10.1038/npjpcrm.2014.71
  45. Basheti IA, Armour CL, Bosnic-Anticevich SZ, Reddel HK. Evaluation of a novel educational strategy, including inhalerbased reminder labels, to improve asthma inhaler technique. Patient Educ Couns 2008;72:26-33.
  46. Ovchinikova L, Smith L, Bosnic-Anticevich S. Inhaler technique maintenance: gaining an understanding from the patient's perspective. J Asthma 2011;48:616-24. https://doi.org/10.3109/02770903.2011.580032
  47. Ovchinikova LA. "Knowing how" is not enought: a mixed methods exploration of inhaler technique maintenance in patients with asthma. Sydney: University of Sydney; 2014.
  48. Azzi E, Srour P, Amour C, Rand C, Bosnic-Anticevich S. Practice makes perfect: self-reported adherence a possible marker of inhaler technique maintenance. Res Social Adm Pharm 2016;12:e37-8.
  49. Alismail A, Song CA, Terry MH, Daher N, Almutairi WA, Lo T. Diverse inhaler devices: a big challenge for health-care professionals. Respir Care 2016;61:593-9. https://doi.org/10.4187/respcare.04293
  50. Davis KH, Su J, Gonzalez JM, Trudeau JJ, Nelson LM, Hauber B, et al. Quantifying the importance of inhaler attributes corresponding to items in the patient satisfaction and preference questionnaire in patients using Combivent Respimat. Health Qual Life Outcomes 2017;15:201. https://doi.org/10.1186/s12955-017-0780-z
  51. Miravitlles M, Montero-Caballero J, Richard F, Santos S, Garcia-Rivero JL, Ortega F, et al. A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD. Int J Chron Obstruct Pulmon Dis 2016;11:407-15.
  52. Riley JH, Tabberer M, Richard N, Donald A, Church A, Harris SS. Correct usage, ease of use, and preference of two dry powder inhalers in patients with COPD: analysis of five phase III, randomized trials. Int J Chron Obstruct Pulmon Dis 2016;11:1873-80. https://doi.org/10.2147/COPD.S109121
  53. van der Palen J, Thomas M, Chrystyn H, Sharma RK, van der Valk PD, Goosens M, et al. A randomised open-label crossover study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices. NPJ Prim Care Respir Med 2016;26:16079. https://doi.org/10.1038/npjpcrm.2016.79
  54. Jahedi L, Downie SR, Saini B, Chan HK, Bosnic-Anticevich S. Inhaler technique in asthma: how does it relate to patients' preferences and attitudes toward their inhalers? J Aerosol Med Pulm Drug Deliv 2017;30:42-52. https://doi.org/10.1089/jamp.2016.1287
  55. Terzano C. Pressurized metered dose inhalers and add-on devices. Pulm Pharmacol Ther 2001;14:351-66.
  56. Newman SP. Inhaler treatment options in COPD. Eur Respir Rev 2005;14:102-8. https://doi.org/10.1183/09059180.05.00009605
  57. Newman SP. Principles of metered-dose inhaler design. Respir Care 2005;50:1177-90.
  58. Kaur I, Aggarwal B, Gogtay J. Integration of dose counters in pressurized metered-dose inhalers for patients with asthma and chronic obstructive pulmonary disease: review of evidence. Expert Opin Drug Deliv 2015;12:1301-10. https://doi.org/10.1517/17425247.2015.1000858
  59. Lavorini F, Mannini C, Chellini E, Fontana GA. Optimising inhaled pharmacotherapy for elderly patients with chronic obstructive pulmonary disease: the importance of delivery devices. Drugs Aging 2016;33:461-73. https://doi.org/10.1007/s40266-016-0377-y
  60. Dal Negro RW, Bonadiman L, Turco P. Prevalence of different comorbidities in COPD patients by gender and GOLD stage. Multidiscip Respir Med 2015;10:24. https://doi.org/10.1186/s40248-015-0023-2
  61. Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med 2005;18:264-72. https://doi.org/10.1089/jam.2005.18.264
  62. Anderson P. Use of Respimat Soft Mist inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis 2006;1:251-9.
  63. Dekhuijzen PN, Vincken W, Virchow JC, Roche N, Agusti A, Lavorini F, et al. Prescription of inhalers in asthma and COPD: towards a rational, rapid and effective approach. Respir Med 2013;107:1817-21. https://doi.org/10.1016/j.rmed.2013.09.013

피인용 문헌

  1. Pharmacotherapy for chronic obstructive pulmonary disease vol.61, pp.9, 2018, https://doi.org/10.5124/jkma.2018.61.9.545
  2. Review of Drug Development Guidance to Treat Chronic Obstructive Pulmonary Disease: US and EU Perspectives vol.106, pp.6, 2018, https://doi.org/10.1002/cpt.1540
  3. Maintenance inhaler therapy preferences of patients with asthma or chronic obstructive pulmonary disease: a discrete choice experiment vol.75, pp.9, 2018, https://doi.org/10.1136/thoraxjnl-2019-213974
  4. Comparing Inhaler Use Technique Based on Inhaler Type in Elderly Patients with Respiratory Disease vol.84, pp.1, 2018, https://doi.org/10.4046/trd.2020.0021
  5. Updated view on the treatment of chronic obstructive pulmonary disease in Korea vol.64, pp.3, 2018, https://doi.org/10.5124/jkma.2021.64.3.225